The estimated Net Worth of Adrian Senderowicz is at least $1.22 millió dollars as of 16 June 2022. Adrian Senderowicz owns over 27,858 units of Puma Biotechnology Inc stock worth over $67,500 and over the last 9 years he sold PBYI stock worth over $813,118. In addition, he makes $337,201 as Independent Director at Puma Biotechnology Inc.
Sign up
Adrian Senderowicz PBYI stock SEC Form 4 insiders trading
Adrian has made over 8 trades of the Puma Biotechnology Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 27,000 units of PBYI stock worth $89,910 on 13 June 2024.
The largest trade he's ever made was selling 40,993 units of Puma Biotechnology Inc stock on 11 June 2021 worth over $457,892. On average, Adrian trades about 7,722 units every 84 days since 2015. As of 16 June 2022 he still owns at least 27,000 units of Puma Biotechnology Inc stock.
You can see the complete history of Adrian Senderowicz stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Adrian Senderowicz biography
Dr. Adrian Senderowicz M.D. serves as Independent Director of the Company.D., is Independent Director of the Company. Dr. Senderowicz has been a director since August 2015. Dr. Senderowicz has been Senior Vice President and Chief Medical Officer of Constellation Pharmaceuticals, Inc., a private clinical-stage biopharmaceutical company focusing on the development of novel tumor-targeted and immuno-oncology therapies, since July 2017. Dr. Senderowicz served as Senior Vice President and Chief Medical Officer of Cerulean Pharma Inc., a public clinical-stage company developing nano-particle conjugates, from September 2015 until June 2017. Dr. Senderowicz served as the Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs from August 2014 to February 2015, and Clinical and Regulatory Strategy Officer from February 2015 to March 2015 of Ignyta, Inc., a public precision oncology biotechnology company. Prior to joining Ignyta, Dr. Senderowicz was Vice President, Global Regulatory Oncology at Sanofi, a position he held from September 2013 to August 2014. Prior to Sanofi, Dr. Senderowicz was Chief Medical Officer and Vice President, Medical Development at Tokai Pharmaceuticals, Inc. from August 2012 to March 2013. From August 2008 to March 2012, Dr. Senderowicz held positions of increasing responsibility, including Senior Medical Director, Oncology Clinical Development, at AstraZeneca. Before his tenure at AstraZeneca, Dr. Senderowicz spent almost four years in a variety of leadership positions at the U.S. Food and Drug Administration Division of Oncology Drug Products in the Center for Drug Evaluation and Research. Prior to his work with the U.S. Food and Drug Administration (“FDA”), Dr. Senderowicz held a variety of clinical and research positions, including Coordinator of the Prostate Cancer Drug Development Clinic and Investigator and Chief, Molecular Therapeutics Unit, with the National Cancer Institute/National Institutes of Health.
What is the salary of Adrian Senderowicz?
As the Independent Director of Puma Biotechnology Inc, the total compensation of Adrian Senderowicz at Puma Biotechnology Inc is $337,201. There are 13 executives at Puma Biotechnology Inc getting paid more, with Alan H. Auerbach having the highest compensation of $5,693,423.
How old is Adrian Senderowicz?
Adrian Senderowicz is 56, he's been the Independent Director of Puma Biotechnology Inc since 2015. There are 6 older and 8 younger executives at Puma Biotechnology Inc. The oldest executive at Puma Biotechnology Inc is Jay Moyes, 66, who is the Lead Independent Director.
What's Adrian Senderowicz's mailing address?
Adrian's mailing address filed with the SEC is 215 First St Suite 200, Cambridge, MA 02142, USA.
Insiders trading at Puma Biotechnology Inc
Over the last 13 years, insiders at Puma Biotechnology Inc have traded over $168,440,369 worth of Puma Biotechnology Inc stock and bought 2,655,298 units worth $48,866,148 . The most active insiders traders include Capital Partners Gp, L.L.C...., Steven Lo és Troy Edward Wilson. On average, Puma Biotechnology Inc executives and independent directors trade stock every 18 days with the average trade being worth of $60,225. The most recent stock trade was executed by Michael Patrick Miller on 12 August 2024, trading 23,358 units of PBYI stock currently worth $81,519.
What does Puma Biotechnology Inc do?
we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
What does Puma Biotechnology Inc's logo look like?
Complete history of Adrian Senderowicz stock trades at Puma Biotechnology Inc és Constellation Pharmaceuticals Inc
Puma Biotechnology Inc executives and stock owners
Puma Biotechnology Inc executives and other stock owners filed with the SEC include:
-
Alan H. Auerbach,
Founder, Chairman, Pres, CEO & Sec. -
Jeffrey Jerome Ludwig,
Chief Commercial Officer -
Alan Auerbach,
Chairman of the Board, President, Chief Executive Officer -
Douglas Hunt B.Sc., FRAPS,
Sr. VP of Regulatory Affairs, Medical Writing & Project Management -
Maximo F. Nougues,
CFO & Principal Accounting Officer -
Douglas Hunt,
Senior Vice President, Regulatory Affairs, Medical Writing and Project Management -
Richard Bryce,
Chief Medical and Scientific Officer -
Ann Miller,
Independent Director -
Dr. Richard P. Bryce,
Chief Medical & Scientific Officer -
Maximo Nougues,
Chief Financial Officer -
Hugh O Dowd,
Independent Director -
Jay Moyes,
Lead Independent Director -
Troy Wilson,
Independent Director -
Adrian Senderowicz,
Independent Director -
Michael Miller,
Independent Director -
Mariann Ohanesian,
IR Contact Officer -
Brian Stuglik,
Director -
Dr. Alvin F. Wong,
Chief Scientific Officer -
Charon Spencer Sr.,
VP of HR -
Steven Lo,
Chief Commercial Officer -
Capital Partners Gp, L.L.C....,
-
Robert Charnas,
-
Richard Benton Phillips,
SEE REMARKS -
Charles R Eyler,
SEE REMARKS -
Frank Zavrl,
Director -
Thomas Malley,
Director -
Jeffrey Jerome Ludwig,
Chief Commercial Officer -
Alvin F Wong,
Chief Scientific Officer -
Allison Dorval,
Director -
Alessandra Cesano,
Director